Rizatriptan drug interactions: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Rizatriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Drug Interactions== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | ====7.1 Propranolol==== | ||
The dose of MAXALT should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. | |||
====7.2 Ergot-Containing Drugs==== | |||
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and MAXALT within 24 hours is contraindicated[see Contraindications (4)]. | |||
====7.3 Other 5-HT1 Agonists==== | |||
Because their vasospastic effects may be additive, co-administration of MAXALT and other 5-HT1 agonists within 24 hours of each other is contraindicated [see Contraindications (4)]. | |||
====7.4 SSRIs/SNRIs and Serotonin Syndrome==== | |||
Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7)]. | |||
====7.5 Monoamine Oxidase Inhibitors==== | |||
MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite [see Contraindications (4) and Clinical Pharmacology (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 07:16, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Drug Interactions
7.1 Propranolol
The dose of MAXALT should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
7.2 Ergot-Containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and MAXALT within 24 hours is contraindicated[see Contraindications (4)].
7.3 Other 5-HT1 Agonists
Because their vasospastic effects may be additive, co-administration of MAXALT and other 5-HT1 agonists within 24 hours of each other is contraindicated [see Contraindications (4)].
7.4 SSRIs/SNRIs and Serotonin Syndrome
Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7)].
7.5 Monoamine Oxidase Inhibitors
MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite [see Contraindications (4) and Clinical Pharmacology (12.3)].[1]
References
Adapted from the FDA Package Insert.